Allergy & Immunology
Expert discussions on allergic conditions, immunodeficiencies, drug hypersensitivity, and immunotherapy approaches.
Recent Discussions
Do you generally favor nebulizers, HFAs or other devices in children aged 5 and younger with asthma?
When used correctly, MDI used with a spacer has been shown to be clinically equivalent in terms of efficacy and safety (Dhuper et al., PMID 19081697; Cates et al., PMID 24037768). Treatment with MDIs also offers a broader range of controller medication options, offering maximum flexibility for treat...
What treatments do you consider for cholinergic urticaria refractory to high dose H1 blockers and omalizumab?
Generally, my initial approach to cholinergic urticaria (CholU) is the same for chronic spontaneous urticaria and other forms of chronic inducible urticaria [1]. Most patients with antihistamine-refractory cholinergic urticaria (CholU) will respond to omalizumab 300 mg monthly. Those individuals wit...
Would you consider prescribing NAC for a patient with OCD and a documented sulfa allergy?
I would consider using NAC if needed in a patient with a documented sulfa allergy because, although NAC is a sulfur-containing compound, it is chemically different from sulfonamides.However, as with any new medical trial on a patient, individual hypersensitivity is a possibility. Provided there is a...
Based upon recently published information in the journal Science, would you offer zileuton to a high-risk food allergy patient who declines oral immunotherapy and omalizumab?
The data suggests that zileuton was not effective in preventing anaphylaxis.
Which patient characteristics or scenarios drive you to choose tezepelumab over dupilumab for asthma?
I typically put adult patients with T2 high, and allergic phenotype on dupilumab whereas those that are T2 high only or T2 low are on tezepelumab. Additionally, if the patient has nasal polyps or AD, then I would prefer dupilumab over tezepelumab. I always have a discussion with the patient regardin...
Is there any genetic testing available for the CDHR3 receptor?
A common variant in CDHR3, Cys529Tyr, leads to susceptibility to a variety of respiratory symptoms, including symptomatic rhinovirus, asthma, chronic rhino sinusitis and more. Depending on the ethnic background, between 15%-35% of the population carries at least one copy. There are no clinical uses ...
Do you routinely consider FDG PET/CT imaging for workup of fever of unknown origin?
The landscape of FUO and IUO and our clinical approach to diagnosing its cause has changed significantly over the past several decades. More sensitive microbiologic screening for infectious etiologies, including syndromic molecular panels and next-generation sequencing are now clinically available a...
How do you reassure families that no allergy testing is needed for urticaria?
There used to be a Choosing Wisely message about this. Here is a video on it. Diagnostic Testing and Chronic Urticaria Video - AAAAI The 2014 practice parameters on chronic urticaria also discuss this. The practice parameter update is looking at this in a GRADE fashion and will likely have even mo...
When would you pursue genetic testing for severe recalcitrant atopic dermatitis?
Not an easy question to answer, but severe and treatment-refractory AD, especially if early onset, is concerning for immune dysregulation and should warrant immune evaluation early. By treatment-refractory, I do not just mean topical therapies, but attempts to control the Th2 pathway that fail repea...
What factors do you consider prior to offering a trial of ICS/LABA therapy versus a methacholine challenge test in patients with suspected asthma but normal pulmonary function testing?
If there is a high suspicion of asthma, have the patient obtain a portable electronic spirometer. If peak flows/FeV1 drops >15% correlate with symptoms, start Rx and follow spiro results. If low suspicion for asthma or very mild symptoms, do methacholine.